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Abstract
A profusion of new applications for phage technologies has been developed 
within the last few years, stimulating investigations into the large-scale production 
of different phages. Applications such as antibiotic replacement, phages as gene 
therapy vectors, phages as vaccines, diagnostics using filamentous phages and novel 
optical applications such as the phage laser may need grams to kilogrammes of 
phage in the future. However, many of the techniques that are used for the growth 
and purification of bacteriophage at small scale are not transferable to large-scale 
production facilities of phage in industrial processes. In this chapter, the stages 
of production that need to be carried out at scale are examined for the efficient 
large-scale fermentation of the filamentous phage M13 and the Siphoviridae phage 
lambda (λ). A number of parameters are discussed: the multiplicity of infection 
(MOI) of phage to host cells, the impact of agitation on the initial infection stages, 
the co-growth with phage rather than static attachment, the use of engineered host 
cells expressing nuclease, the optimisation of both the quantity and the physiology 
of the E. coli inoculum and phage precipitation methods.
Keywords: phage, PEG precipitation, nuclease, filamentous phage, lambda,  
phage diagnostics, phage laser, fermenter
1. Introduction
Bacteriophages, often shortened to just phages, are viruses that infect bacteria. 
Their discovery and characterisation in the early days of bacterial molecular biology 
has led to certain phages being very well understood in terms of their life cycle, and 
several phages that infect Escherichia coli have become tools in molecular biology 
techniques such as cloning [1–3]. There has been a resurgence recently in the use 
of bacteriophages as therapeutics, as vectors for the delivery of vaccines [4], for 
the killing of pathogenic bacteria as an alternative to antibiotics [5] and for gene 
therapy to transfer DNA to target human or animal cells [6]. Some of these uses 
would need the production of many millions of doses of a vaccine, for example, 
or very large quantities for use as an antibacterial. This has increased demand for 
investigation into the large-scale production of bacteriophage which would necessi-
tate volumes from hundreds to thousands of litres. The use of phage as biotherapeu-
tics such as vaccines or for gene therapy may be advantageous as phage is considered 
cheap to manufacture, with large quantities of the product being rapidly produced. 
But the large-scale production of wild type or genetically modified bacteriophages 
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for use in the biotherapeutics industry provides significant process and regulatory 
challenges. Bacteriophages, like any virus, are dependent on a host organism to 
propagate, in the examples here it is E. coli; consequently, the generation of progeny 
bacteriophage is unequivocally linked to the physiology, molecular biology and 
growth needs of the host which are important to understand in order to maximise 
production.
Methods for the production of phages, e.g. λ and M13 bacteriophage, at labora-
tory production scale have remained unchanged for many years [7]. However, 
aspects of these protocols are either not practical or unsuitable for large-scale 
production of phages. Therefore, it is highly desirable to consider early on in the 
development of phage technologies how any successful bacteriophage therapeutic 
would be produced at large scale at an industrial level.
One of the problems associated with producing and using λ as a biotherapeutic is 
the issue of host-derived nucleic acid. The λ lifecycle [8] involves the phage progeny 
escaping from the host cell by lysis of the bacteriophage host, whereupon the cell 
contents including high-molecular-weight host chromosomal DNA and RNA are 
released into the culture supernatant. This significant quantity of host cell-derived 
nucleic acid can cause important problems for both downstream processing [9] 
and from a regulatory point of view [10], so reducing the presence of bacterial host 
nucleic acid in the first stages of the process stream would remove these issues.
M13 is an unusual phage because it does not lyse its host and the entire phage is 
secreted from the host bacterium through special pores spanning the cell wall [11] 
although this does make the culture supernatant relatively free of contaminating 
host cell material, unlike the supernatant in a λ fermentation. In both lytic and 
secreted phage production the first downstream stage is the concentration of the 
phage from whatever volume of growth medium was used to grow the infected 
cells. Filamentous phage such as M13 has a very asymmetric shape with wild-type 
M13 having a length to width ratio of 138:1 and this extreme asymmetry allows a 
mild precipitation using polyethylene glycol (PEG) [12].
In this paper we present initial studies into the parameters that need to be 
manipulated for scaling up fermentation of M13 phage for industrial production.
2. Lambda phage
Lambda (λ) bacteriophage is a temperate phage with a double-stranded (ds) 
genome of approximately 48 kb [13]. This is encapsulated in an icosahedral capsid 
(~50 nm in diameter) with a long flexible non-contractile tail (~150 nm in length). 
The host for λ production is E. coli with infection by lambda phage taking place 
via the maltose binding protein, LamB. Lambda bacteriophage is one of the most 
intensely studied bacteriophages and has been used for many studies on uncovering 
basic molecular biology [14] and in biotechnology for phage display of peptides and 
proteins [15], vaccine [16] and gene transfer and therapy [6].
The large-scale production of genetically modified lambda bacteriophage for 
use in the biotherapeutics industry provides significant process and regulatory 
challenges.
One of the problems associated with producing and using lambda bacteriophage 
as a biotherapeutic is the issue of host-derived nucleic acid. The lambda lifecycle 
involves the cell lysis of the bacteriophage host, whereupon high-molecular-weight 
host chromosomal DNA is liberated into the culture supernatant. The presence of 
large quantities of host cell-derived nucleic acid can cause significant problems 
during processing as high-molecular-weight chromosomal DNA causes an increase 
in the cell lysate viscosity [9]. Furthermore, the presence of nucleic acid in the final 
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product is non-desirable from a regulatory perspective [10], and thus reducing its 
presence in the first stages of the process stream would alleviate these issues. The 
lysis of the host E. coli cell and the release of intracellular contents (DNA, RNA 
and proteins) as well as fragments of cell wall will have detrimental effects when 
processing lambda. For example, intracellular contents can co-precipitate with 
the phage, can compete for binding sites on chromatography material and can 
block membranes and chromatography columns. These contaminants need to be 
taken into consideration when planning a large-scale purification and downstream 
processing protocol.
3. M13: a filamentous bacteriophage
M13 is an unusual phage as it has a filamentous structure of 900 nm in length 
and 6.5 nm in width. It is a member of a small group of closely related phages 
including F1 and Fd [17] that infect E. coli. The genome is a single-stranded circular 
DNA molecule, and the length of the phage (but not its width) is simply determined 
by the size of the page genome. Short phage particles can be made using plasmids 
that contain just the replication origin and packaging signals, and phage particles 
longer than the wild type can be made by inserting DNA sequences into the phage 
genome. It was thought that the very long but thin shape of M13 and other filamen-
tous phages would increase their shear sensitivity in the various kinds of industrial-
scale processing equipment of pumps, continuous centrifuges and membrane 
filters. This was seen not to be the case [18] which is highly advantageous for large-
scale downstream processing of this and other filamentous phages. Filamentous 
phages have a rather special property in that they do not lyse their host, but set up 
a permanently infected state, and new, progeny phage is extruded through special 
structures in the cell wall. Derivatives of M13 phage were extensively used in the 
early years of DNA sequencing by the Sanger method [19] and in the techniques of 
site-directed mutagenesis [20] and phage display [21] for the maturation of recom-
binant antibodies [22].
The unusual mode of growth of filamentous phage by secretion from the host 
without lysis has considerable advantages for these molecular biology methods 
because the phage in the supernatant of growing cells is relatively free of any cel-
lular contaminants [23] such as intracellular proteins, genomic DNA and RNA. This 
makes the purification of filamentous phage a relatively simple matter with many 
fewer contaminants than phage λ cultures.
4. Multiplicity of infection (MOI)
The multiplicity of infection or MOI is the number of phage particles added per 
host cell to initiate infection and thus production. The methods developed for the 
uses of phage λ and M13 at small scale or a few mL generally tend to use a high MOI 
of 5–10 or more. The MOI is important for scale-up as it defines how large the cul-
ture that provides the phage for the scale-up needs to be. It is neither desirable nor 
sensible to have to grow a fermenter of phage to inoculate a slightly larger fermenter 
in the final preparation. Also with a large MOI of just under 10, we reach the point 
where there will be enough phage for every cell to be infected, and at that MOI we 
can only expect a single burst of phage particles for lytic phage and therefore only a 
small increase in the number of phage added. With an MOI of 1, only 63% of cells 
will be infected by one or more phages because there is a Poisson distribution of 
MOI to infected cells [24]. But some phages have many binding sites per cell, e.g. 
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T4 has 105 molecules of OmpC to bind to [25], while M13 only has approximately 3 
[26], so the kinetics of phage finding and attaching to bacteria and forming a pro-
ductive infection are quite complex. There are 30,000 LamB proteins in the outer 
membrane which is the initial receptor for λ but many fewer copies of the mannose 
receptor, ManY, in the inner membrane which is where the DNA of λ crosses the 
inner membrane [27, 28]. For M13 the receptor is the tip of the F plasmid’s transfer 
pilus, and there are usually one or two F pili per cell. But once M13 has established 
its replication inside an E. coli host, the cell is then permanently infected and will 
continue to secrete phage from these intact cells.
Under ideal conditions the burst size of λ phage particles is 170 +/− 10 which 
takes 51 min [29], and during this time uninfected cells will still be growing and 
dividing, providing new hosts for the phage that are released. To get repeated rounds 
of replication, the ideal cell numbers and MOI for each phage are different and take 
into account cell division rates, numbers of receptors, the choice between a lytic and 
lysogenic cycle in phages where those can take place, the burst size and rate of repli-
cation and maturation of the phage. This complex interaction of several parameters 
means that it is difficult to say a priori what the combination of cells, phage and time 
of addition is the most appropriate for a given size of growth chamber.
Figure 1 shows the relationship between the host E. coli and MOI of M13.
The graph of MOI and final phage production in Figure 1 shows that from a 106 
range of MOI added at the start of growth in Figure 1, all three cultures reach the same 
final M13 phage titre. It just takes slightly longer for the lower MOI cultures to reach 
the final of approx. 5 × 1011 phage per mL. This has important consequences for scale-
up of M13 production. For example, if a large fermenter of, say, 100 L were needed and 
the MOI of 50:1 was needed, we would need to have 500 mL of the equivalent inocu-
lum used here. The information from Figure 1 shows that we can use just 0.5 mL of 
the same titre inoculum or much less, e.g. down to a few microlitres. For convenience 
it is best to inoculate a fermenter with enough in terms of volume that will reach the 
medium in the fermenter, so a few millilitres of a phage dilution are all that is needed. 
This means that one phage stock can be used for multiple fermentation runs.
Figure 1. 
Titre of M13 produced from different MOI on E. coli TOP10 F′. M13 phage was prepared from a 400 mL 
culture of E. coli TOP10 F′ and precipitated with PEG 6000 at a final concentration of 3.3% and 330 mM 
NaCl. The precipitated phage was centrifuged at 14,000 ×g for 10 min at 4°C and resuspended in 8 mL of 
10 mM Tris.HCl pH 7.5 and filtered through a 0.22 μm filter. The stock of M13 was approximately 1 × 1012  
pfu/mL. E. coli TOP10 F′ was grown in 400 mL of Nutrient Broth No. 2 (Oxoid) and a 40-mL inoculum in 
2-L shake flask at 37°C. Around 2 mL of M13 was added at the appropriate dilutions to achieve the three 
different MOI of 0.00005:1, 0.05:1 and 50:1. Each point is the average of three flasks.
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5. Initial phage binding and infection in fermenters
The standard way of initiating infection of λ or M13 is to mix the phage and 
cells and allow a static incubation for usually 5–15 min for phage attachment to the 
phage binding target on the cell surface. The phage/cell mixture is then added to 
broth if liquid growth is desired or to 3 mL of soft agar and poured onto an agar 
plate if plaques are wanted. This static incubation is in the recipes for all phages 
being handled at the lab scale and probably came about because researchers thought 
it would maximise the attachment of phage to their host. However, in a fermenter 
it is not sensible to turn off the stirrer and let the cells sit for 15 min while phage 
attachment takes place. We tested what would happen if M13 phage were simply 
added directly to shaking cultures of E. coli JM107 without stopping the shaking and 
comparing this with a static attachment/incubation of 30 min.
Figure 2 shows this experiment with three different inocula of M13 phage giving 
MOI ranging over a 106 range.
It is clear from Figure 2 that the static incubation is not needed for the initial 
attachment of M13 to sensitive E. coli, and so the required dose of M13 phage can be 
directly added to a fermenter with the E. coli host already growing with the impeller 
stirring. The culture which will be stirred at a high rate does not need to be stopped 
and left to go static for 15–30 min. This would compromise the growth of the cells in 
a large fermenter, and so our findings give a positive help for the scale-up of phage 
and the way one can run a large fermenter where procedures have to be different 
from what is done at small scale in the molecular biology lab.
6. Nuclease-producing E. coli
The above sections on MOI and removing the necessity for a static attachment 
of phage were shown with M13 as examples. The M13 phage does not lyse its host, 
so the culture medium after infection is uncontaminated by the bulk of the host cel-
lular contents and largely contains just the filamentous M13 bacteriophage particles. 
We have examined the supernatants from M13-infected cultures and determined 
the levels of host cell contaminants of DNA and protein [23] which are quite low 
Figure 2. 
Static versus shaking incubation of M13 with E. coli TOP10 F′. The conditions and culture quantities were 
identical to those shown in Figure 1 with the addition of three conditions at each MOI where the M13 phage 
was added and left for 30 min static incubation. These cultures for the static incubation were then grown with 
shaking at 200 rpm in a 37°C orbital incubator. Each point is the average of three flasks.
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compared to the large amount of cellular DNA, RNA and protein released by lytic 
phage. A phage such as λ is a representative of lytic phage which is the majority of 
the types of phages used in therapy and biological control for the replacement of 
antibiotics. At each cycle of replication and release of the new phage particles, the 
host is lysed, and the cell contents are released into the medium along with insolu-
ble debris from the cell wall and membrane. This leads to problems in subsequent 
downstream purification due to the large amount of different cellular molecules 
competing in the subsequent downstream processing steps.
The host RNA and DNA represent major contaminants that need to be removed 
especially for gene therapy applications. The release of host cell DNA also increases 
the viscosity of the medium, and this has an adverse effect on clarification by 
centrifugation and membrane concentration due to blocking of the membranes. 
For lab-scale molecular biology work, it is normal to add the enzymes pancreatic 
RNAseI and pancreatic DNAseI from bovine pancreas preparations. With the 
advent of bovine spongiform encephalopathy (BSE) which peaked in the 1990s, 
the addition of any bovine or animal proteins into the growth or purification train 
of material destined for human therapy was banned. These regulatory restrictions 
removed the ability to use these cheap nucleic acid-degrading enzymes, and the 
substitutes from bacterial sources were much more expensive. A strategy to over-
come this problem was developed by us, and this was to express a broad-spectrum 
nuclease in the periplasm of E. coli which would be released as cells were lysed 
[30, 31]. The enzyme Staphylococcal nuclease has been extensively characterised 
and used from the 1960s onwards [32] and can degrade both DNA and RNA. The 
expression of this in E. coli where it is secreted into the periplasm does not affect 
the growth of E. coli because the enzyme cannot get access to its substrate while 
the cell is growing normally. When the cells are lysed by a bacteriophage such as λ 
or by homogenisation, the nuclease can gain access to the released DNA and RNA 
and degrade them. This ‘cell engineering’ approach to assisting bioprocessing was 
developed at UCL and has been shown to give considerable gains in the centrifuga-
tion steps and other downstream purification steps in bioprocessing of proteins 
such as Fab fragments [33–35].
We sought to apply this cell engineering strategy for the production of λ phage 
and to help solve the problem of the large amount of cellular contaminants released 
into the media when λ phage cultures need to be harvested and processed.
E. coli JM107 [3] was grown in 2 L fermenters with either JM107 or JM107 
containing the plasmid pMMBompnucB which is a broad host-range plasmid vector 
based on an Inc. Q plasmid RSF1010 and contains the Staphylococcal nuclease 
which has been altered by the addition of the E. coli ompA signal sequence for 
secretion [31]. Figure 3 shows the growth of the two hosts with no added λ phage 
and the same hosts with 8 × 1010 λ phage particles added after 2 hours when the 
OD600 had reached 10.
The addition of λ to the fermenter used the strategy that we had developed 
where a low MOI is used and without a static initial incubation of the host cells 
and the phage. In this way we can add the phage directly to a growing fermenter of 
host with the impeller (single shaft with three top-driven, equally spaced, six-
bladed turbines) and four diametrically opposed baffles in the fermenter, running 
throughout. The growth profiles of the two uninfected cultures show no difference 
in their growth profiles which means that the presence of the expressed nuclease 
enzyme in the periplasm has no effect on growth rate or final OD. In the two 
cultures with added λ phage, the OD drop is the same for both hosts showing that λ 
replication and cell lysis are the same in both.
The production of λ was monitored throughout growth and is shown in 
Figure 4.
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Both the nuclease and the non-nuclease-expressing E. coli JM107 produced the 
same 5-log increase in phage particles with the same time profile. The efficacy of the 
nuclease in the removal of the host nucleic acid was assessed by the electrophoresis 
of samples from each time point on agarose gels and the visualisation of the released 
nucleic acid (both DNA and RNA). Figure 5 shows the complete degradation and 
removal of the released host genomic DNA and host RNA in the strain of E. coli 
expressing the periplasmic nuclease.
The presence of the expressed periplasmic nuclease is apparent from the dif-
ference in the samples in Figure 5B compared to the samples from the same time 
points in the fermenter with no expression plasmid for the Staphylococcal nuclease. 
Figure 3. 
Growth of E. coli JM107 and λ production with and without a nuclease-expressing plasmid. E. coli JM107 
containing pMMBompnucB and with no plasmid was grown in 2 L (working volume 1.5 L) LH 210 series 
fermenter (Bioprocess Engineering Services, Charing, Kent, UK) with 150 mL of E. coli inoculum and a 
final working volume of 1.5 L in phage media containing 100 μg/mL ampicillin and 20 μg/mL IPTG. λ phage 
particles were added at 2 hours to give an MOI of 0.05 (4 mL of 2 × 1010 pfu/mL). Impeller stirring continued 
throughout the growth and addition of phage, and the OD600 was monitored.
Figure 4. 
Production of λ phage in 2 L fermenters with and without periplasmic nuclease expression. λ phage was added 
at 2 hours in Figure 3, and the graph here shows λ phage amounts from the 2 hours onwards. Samples from the 
fermenters shown in Figure 3 were diluted in phage buffer and titred on E. coli JM107 using soft top agar and 
plaque counting.
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Almost all of the released host genomic DNA and the large majority of the RNA has 
been degraded in the culture that expresses the nuclease. Figure 4 shows that the 
production of λ phage particles is identical in both fermenters, and the presence of 
the nuclease does not impinge on λ production and leads to a removal of the major-
ity of the nucleic acid that would normally need the addition of bovine pancreatic 
DNAseI and RNAseA or more expensive bacterial equivalents such as Benzonase™ 
[36] to reduce the amount of nucleic acids. This cell engineering approach means 
that no animal-derived enzymes need be added, no costly commercial bacterial 
enzymes need be added and the engineered cells provide their own nuclease which 
degrades the nucleic acid in situ, so no additional time for incubation of any added 
enzyme is needed. Therefore a saving of both time and money is achieved via cell 
engineering for bioprocessing.
7. Precipitation of M13
Bacteriophages produced at any scale need to be concentrated by some method 
after the growth and production have taken place. The properties of phages allow 
some precipitation methods that are milder than conditions needed to precipitate 
host soluble protein or nucleic acid. Phages are large multicomponent entities usually 
many hundreds of times larger than a medium-sized soluble protein. Their asym-
metric shape also enables mild precipitation methods. Polyethylene glycol (PEG) 
precipitation is a mild method of precipitating biological material and is very effica-
cious in the precipitation of large asymmetric material such as DNA or macromolec-
ular assemblies, e.g. virus-like particles such as phages [37, 38]. The larger and more 
asymmetric the particle, the lower the amount of PEG is needed to precipitate the 
particle and leave behind other smaller soluble materials. An exploration of different 
average molecular weights of PEG from 600 to 20,000 for M13 precipitation showed 
that PEG 6000 and PEG 8000 combined the best properties of precipitation at low 
% concentration with lower viscosities than PEG 12,000 and PEG 20,000 [23] and 
2% PEG 6000 with 330 mM NaCl gave >95% precipitation of M13. The relationship 
between PEG and NaCl is shown in Figure 6 where the increasing PEG molecular 
weight and PEG concentration with % of M13 recovered were investigated.
Figure 5. 
Degradation of host nucleic acid from l infected E. coli JM107 and JM107 containing pMMBompnucB. 
(A) Agarose gel with samples from fermenter in Figure 3 growing E. coli JM107 with λ. 1, 1 kb ladder; 2, 0 h; 3, 
1 h; 4, 2 h; 5, 3 h; 6, 4 h; 7, 5 h; 8, 6 h; 9, 7 h; 10, 8 h; 11 λ HindIII ladder. (B) Agarose gel with samples from 
fermenter in Figure 3 growing E. coli JM107 containing pMMBompnucB infected with λ. 1, 1 kb ladder; 2, 0 h; 
3, 1 h; 4, 2 h; 5, 3 h; 6, 4 h; 7, 5 h; 8, 6 h; 9, 7 h; 10, 8 h; 11 λ HindIII ladder. The same volume of sample from 
each fermenter time point was loaded onto each lane.
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The diagram in Figure 6 shows the relationship between increasing chain 
length/molecular weight of PEG, the % of PEG and the amount of M13 phage 
recovered. Higher-molecular-weight PEG preparations can be used at low final per-
centages, but there is significant increase in the viscosity of high-molecular-weight 
PEG solutions in the stock solutions needed to add to the phage-containing solu-
tion, making PEG 20,000 very difficult to use. PEG 6000 and PEG 8000 achieve 
virtually the same precipitation profile as PEG 12,000 and the lower viscosity of 
stock solutions of PEG 6000 make this chain length the best for precipitation with 
low viscosity. A concentration of 2% w/v PEG 6000 is ideal with 330 mM NaCl 
[23]. It was discovered that the nutrient media commonly used for growth such 
as NB2 contains sufficient salt (Na, K and NH3 ions) that the added NaCl can be 
reduced to only 135 mM which would make a saving in materials and disposal costs 
in large-scale M13 phage precipitation.
8. Conclusion
The strategies for the scale-up of phage growth and primary downstream purifi-
cation are still in their infancy, but we have shown that there are significant gains to 
be made from the work described here. The amount of phage that needs to be added 
to large-scale growth volumes can be reduced by several orders of magnitude from 
what is common at the lab scale. Phage can be added directly to fermenters where 
rapidly stirring impellers are needed to maintain aeration and correct physiology 
of the host with no cessation of the stirring, and the phage will find their host and 
attach with no difficulty. The use of cells engineered to produce their own broad-
spectrum periplasmic nuclease gives significant gains in the destruction of host DNA 
and RNA release on lysis, and this prevents the contamination of the phage with 
nucleic acid when the phages are concentrated by precipitation. The gentle precipita-
tion method of using low concentrations of PEG can then be used to give relatively 
pure preparations of phage in one step. These methods can be used together and will 
Figure 6. 
The relationship between M13 recovery and PEG molecular weight and percentage PEG. All precipitations 
were carried out at 10 mL scale with additions of PEG to the final % concentration shown in the diagram with 
4 × 1012 CsCl purified M13 and 330 mM NaCl. The mixtures were incubated on ice for 1 hour and centrifuged 
for 10 min at 8000 ×g at 4°C.
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allow the large-scale uses of phage in the future in medical and clinical applications 
and then beyond into biotechnological applications such as the uses of filamentous 
phage in electronics like phage batteries [39] and the phage laser [40].
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